NEW INSIGHTS INTO THE THERAPEUTIC USE OF NITRIC OXIDE-DONATING NON-STEROIDAL ANTI-INFLAMMATORY DRUGS

  • Beatrice Rozalina BUCA “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • Liliana MITITELU-TARTAU “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • R.V. LUPUSORU “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • Catalina Elena LUPUSORU “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • C. REZUS “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Abstract

Nitric oxide (NO), a radical with increased reactivity, diffusibility and instability plays an important role in the regulation of a wide range of physiological processes, including cellular immunity, angiogenesis, cardiac function, neurotransmission, and platelet aggregation. Numerous studies in recent decades have demonstrated the benefits and cytoprotective role of nitric oxide in different body systems. A modern experimental and clinical research direction is represented by the development of hybrids containing a NO donor coupled with a classical nonsteroidal anti-inflammatory agent, (NSAID) demonstrating an improved efficacy and tolerability compared to the administration of the drug alone in laboratory animals, in various experimental models. These agents are obtained by the ester linkage of a NO-releasing moiety to a standard NSAID, such as acetylsalicylic acid (NO-aspirin), ibuprofen (NO-ibuprofen), flurbiprofen (NO-flurbiprofen), naproxen (NO-naproxen), diclofenac (NO-diclofenac) and indomethacin (NO-indomethacin). Multiple pharmacological strategies regarding the release of NO from these hybrid NO-releasing compounds provide new insights into the pathogenesis and treatment of various pathological states, such as: inflammatory conditions, hypertension, atherosclerosis, neoplastic disease, degenerative diseases, colitis and bronchial asthma.

Author Biographies

Beatrice Rozalina BUCA, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Medicine
Department of Morpho-Functional Sciences (II)

Liliana MITITELU-TARTAU, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Medicine
Department of Morpho-Functional Sciences (II)

R.V. LUPUSORU, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Medicine
Department of Morpho-Functional Sciences (II)

Catalina Elena LUPUSORU, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Medicine
Department of Morpho-Functional Sciences (II)

C. REZUS, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Medicine
Department of Medical Specialties (I)

References

1. Vanaja P, Perumal E. Involvement of nitric oxide in learning & memory processes. Indian J Med Res 2011; 133(5): 471-478.
2. Martínez-Ruiz A, Cadenas S, Lamas S. Nitric oxide signaling: classical, less classical, and nonclassical mechanisms. Free Radic Biol Med 2011; 51: 17-29.
3. Iverson NM, Hofferber EM. Stapleton JA. Nitric oxide sensors for biological applications. Chemosensors 2018; 6(8): 1-13.
4. Childers KC, Garcin ED. Structure/function of the soluble guanylyl cyclase catalytic domain. Nitric Oxide 2018; 77: 53-64.
5. Abdellatif KR, Abdelall EK, Bakr RB. Nitric oxide-NSAIDs donor prodrugs as hybrid safe anti-inflammatory agents. Curr Top Med Chem 2017; 17(8): 941-955.
6. Antosova M, Plevkova J, Strapkova A et al. Nitric oxide - important messenger in human body. OJMIP 2012; 2: 98-106.
7. Godínez-Rubí M, Ortuño-Sahagún D. Nitric oxide donors in brain inflammation in A. Barozzi Seabra ed. Nitric Oxide Donors. Novel Biomedical Applications and Perspectives 2017, 263-292.
8. Pawlik M, Pajdo R, Kwiecien S et al. Nitric oxide (NO)-releasing aspirin exhibits a potent esophago-protection in experimental model of acute reflux esophagitis. Role of nitric oxide and proinflammatory cytokines. J Physiol Pharmacol 2011; 62(1): 75-86.
9. Soufli I, Toumi R, Rafa H. Overview of cytokines and nitric oxide involvement in immuno-pathogenesis of inflammatory bowel diseases. World J Gastrointest Pharmacol Ther 2016; 7(3): 353-360.
10. Balez R, Ooi L. Getting to NO Alzheimer's Disease: Neuroprotection versus neurotoxicity mediated by nitric oxide. Oxid Med Cell Longev 2016; 2016: 3806157.
11. Ricciotti E, Dovizio M, Di Francesco L, et al. NCX 4040, a nitric oxide-donating aspirin, exerts anti-inflammatory effects through inhibition of I kappa B-alpha degradation in human monocytes. J Im-munol 2010; 184(4): 2140-2147.
12. Parinandi NL, Sharma A, Eubank TD et al. Nitroaspirin (NCX-4016), a NO donor, is antiangiogenic through induction of loss of redox-dependent viability and cytoskeletal reorganization in endothelial cells. Antioxid Redox Signal 2007; 9:1837-1849.
13. Salvemini D, Kim SF, Mollace V. Reciprocal regulation of the nitric oxide and cyclooxygenase pathway in pathophysiology: relevance and clinical implications. Am J Physiol Regul Integr Comp Physiol 2013; 304(7): R473-87.
14. Napoli C, PaolissoG, Casamassimi A. Effects of Nitric Oxide on Cell Proliferation: Novel Insights. J Am Coll Cardiol 2013; 62(2): 89-95.
15. Momi S, Pitchford SC, Alberti PF et al. Nitroaspirin plus clopidogrel versus aspirin plus clopidogrel against platelet thromboembolism and intimal thickening in mice. Thromb Haemost 2005; 93(3): 535-543.
16. Karthikeyan M, Deepa K. Therapeutic applications of nitric oxide releasing non-steroidal anti- in-flammatory drugs. J Chem Pharm Res 2009; 1(1): 134-147.
17. Gresele P, Marzotti S, Guglielmini G et al. Hyperglycemia-induced platelet activation in type 2 diabetes is resistant to aspirin but not to a nitric oxide-donating agent. Diabetes Care 2010; 33(6): 1262-1268.
18. Ibrahim M, Farghaly E Gomaa W et al. Nitro-aspirin is a potential therapy for non-alcoholic fatty liver disease. Eur J Pharmacol 2011; 659(2-3): 289-295.
19. Song JM, Upadhyaya P, Kassie F. Nitric oxide-donating aspirin (NO-Aspirin) suppresses lung tumor-igenesis in vitro and in vivo and these effects are associated with modulation of the EGFR signaling pathway. Carcinogenesis 2018; bgy049.
20. Fu Y, Wang Z, Chen WL et al. Cardioprotective effects of nitric oxide-aspirin in myocardial ischemia-reperfused rats. Am J Physiol Heart Circ Physiol 2007; 293(3): H1545-52.
21. Baerwald C, Verdecchia P, Duquesroix B. Efficacy, safety, and effects on blood pressure of naprox-cinod 750 mg twice daily compared with placebo and naproxen 500 mg twice daily in patients with osteoarthritis of the hip. Arthritis Rheum 2010; 62(12): 3635-3644.
22. Gresele P. Antiplatelet agents in clinical practice and their haemorrhagic risk. Blood Transfus 2013; 11(3): 349-356.
23. Shen H, Shahzad G, Jawairia M, Association between aspirin use and the prevalence of nonalcoholic fatty liver disease: a cross‐sectional study from the Third National Health and Nutrition Examination Survey. Alim Pharmacol Ther 2014; 40(9): 1066-1073.
24. Buca BR, Mititelu-Tartau L, Lupusoru RV, Popa GE, Rezus C, Lupusoru CE, New nitric oxide donors with therapeutic potential. Rev Med Chir Soc Med Nat Iasi 2016; 120(4): 942-946.
25. Russo I, Viretto M, Barale C. High glucose inhibits the aspirin-induced activation of the nitric ox-ide/cGMP/cGMP-dependent protein kinase pathway and does not affect the aspirin-induced inhibition of thromboxane synthesis in human platelets. Diabetes 2012; diabetes. diabetesjournals.org. 1-9.
Published
2018-06-30